NEW YORK (GenomeWeb News) – PathoGenetix today announced it has secured $10 million in Series C financing to further commercialization efforts for its Genome Sequence Scanning technology.

Participants in the round included existing investors Ascension Health Ventures, Excel Venture Management, and HealthCare Ventures. The funding, PathoGenetix said, will be directed at further development of its first commercial system using the GSS technology, called the Resolution Microbial Genotyping System.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.